DEF: Cardiff Oncology Seeks Stockholder Approval for Increased Equity Incentive Plan and Executive Compensation

Cardiff Oncology is holding its annual meeting of stockholders on June 26, 2025, to vote on key proposals including the election of directors, ratification of the accounting firm, an increase to the equity incentive plan, and executive compensation.

Summary

• Cardiff Oncology is holding its Annual Meeting of Stockholders on June 26, 2025, to vote on several key proposals.
• The proposals include electing seven members to the Board of Directors, ratifying the appointment of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and approving an amendment to the 2021 Equity Incentive Plan to increase the number of issuable shares to 12,150,000 from 8,150,000.
• Stockholders will also vote on an advisory basis to approve the compensation of the company's named executive officers.
• The Board of Directors has set April 28, 2025, as the record date for determining stockholders eligible to vote at the Annual Meeting.
• The company is soliciting proxies and encourages stockholders to vote online or by mail, even if they plan to attend the meeting in person.
• The proxy statement and annual report are available online.
• The Board recommends voting FOR all director nominees, the ratification of BDO USA, P.C., the amendment to the 2021 Equity Incentive Plan, and the approval of the compensation of the named executive officers.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, with a slightly positive sentiment due to the company's efforts to attract and retain talent and its commitment to good corporate governance.

Positives

• The Board is committed to good corporate governance practices.
• The company has established an Audit Committee, a Compensation Committee, and a Corporate Governance/Nominating Committee, each with specific responsibilities.
• The Board believes that the proposed increase in shares authorized for issuance under the 2021 Plan is reasonable and appropriate to attract and retain talent.
• The company has a clawback policy for annual cash incentive awards, long-term incentive awards and any other incentive awards paid to executive officers under certain circumstances.

Negatives

• Approval of the amendment to the 2021 Plan will dilute existing stockholders by an additional 4.9% on a fully diluted basis.
• The company has incurred significant net losses in recent years (e.g., a net loss of $45,431,000 in 2024).

Risks

• If the amendment to the 2021 Plan is not approved, the company might need to use cash to incentivize employees or might not be able to execute on its corporate strategy and retain personnel.
• The company's success depends on attracting and retaining key personnel in a competitive market.
• The company is subject to risks related to clinical development, regulatory approvals, and market acceptance of its products.

Future Outlook

The company aims to continue attracting, retaining, and motivating executive officers and other employees, non-employee directors, and certain consultants in a highly competitive market for employee talent.

Industry Context

As a pre-revenue, oncology-focused biotechnology company based in San Diego, we compete with many other biotech companies in seeking to attract and retain a skilled work force.

Comparison to Industry Standards

• The Compensation Committee compares base salaries, annual incentive opportunities and long-term incentive compensation for each of our executive officers to those of a peer group of similarly sized companies.
• The company generally considers the 50th percentile as a market reference point for base salary within our peer group, and allow for adjustments based on factors specific to the individual executive.
• The company generally considers the 50th to 75th percentiles for annual cash incentive bonus target levels within our peer group, and allow for adjustments based on factors specific to the individual executive.
• The company generally targets the 60th percentile for long term equity incentives within our peer group, and allow for adjustments based on factors specific to the individual executive.
• The 2024 Peer Group includes: Actinium Pharmaceuticals, Inc., Corvus Pharmaceuticals, Inc., Harpoon Therapeutics, Inc., Olema Pharmaceuticals, Inc., ALX Oncology Holdings, Inc., Curis, Inc., Kezar Life Sciences, Inc., Oncternal Therapeutics, Inc., BioAtla, Inc., Cyteir Therapeutics, Inc., Kronos Bio, Inc., Rain Oncology, Inc., Bolt Biotherapeutics, Inc., Elevation Oncology, Inc., MEI Pharma, Inc., Viracta Therapeutics, Inc., Candel Therapeutics, Inc., Genprex, Inc., Mustang Bio, Inc., Werewolf Therapeutics, Inc.

Related Party Transactions

• The Company did not have any related party transactions during the covered period.
• The company has entered into indemnification agreements with its directors and executive officers.

Stakeholder Impact

• Approval of the equity incentive plan amendment will impact shareholders through potential dilution.
• Executive compensation decisions impact shareholders, employees, and the overall company performance.

Next Steps

• Stockholders are encouraged to vote on the proposals before the Annual Meeting on June 26, 2025.
• The company will announce the voting results after the Annual Meeting in a Form 8-K filing with the SEC.

Key Dates

Keywords

equity incentive plan, executive compensation, annual meeting, proxy statement, directors, stockholders, Cardiff Oncology, BDO USA, shares, awards